← back to search

Corrado Tarella

Ripamonti · IT
Area of research
Pathology and Forensic Medicine · Hematology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, and CAR-T cell therapy research.
h-index
52
citations
10,297
works
391
NIH funding
primary concept
Medicine
email

Recent publications

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.
2025cited by 1position: contributordoi
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study
Transplantation and Cellular Therapy 2025cited by 1position: contributordoi
Telomere Length Abnormality: Investigating Approaches and Correlations with Cancer, Bone Marrow Failure and Hematological Malignancies.
2025cited by 0position: contributordoi
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
2024cited by 36position: contributordoi
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
2022cited by 19position: contributordoi
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Blood 2021cited by 95position: middledoi
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term.
2021cited by 3position: contributordoi
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial
Journal of Clinical Oncology 2020cited by 60position: middledoi
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Blood 2019cited by 62position: middledoi
International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20-Positive B Cell PTLD: Clues From the PTLD-1 Trial
American Journal of Transplantation 2015cited by 56position: middledoi
Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial
Blood 2012cited by 28position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 6 papers (2021–2025)Alessandro Rambaldi · Astellas Pharma (United States)3 papers (2021–2025)Umberto Vitolo · Azienda Ospedaliera Citta' della Salute e della Scienza di Torino2 papers (2021–2022)Pier Giuseppe Pelicci · Molecular Oncology (United States)2 papers (2022–2024)Marco Picardi · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1 papers (2020–2020)David A. Rizzieri · Novant Health1 papers (2019–2019) · 1 papers (2020–2020)Ralf Ulrich Trappe · University of Lübeck1 papers (2015–2015)Andrew A. Lane · Harvard University1 papers (2019–2019)Caterina Patti · University of Palermo1 papers (2020–2020)Emanuele Angelucci · Polyclinic Medical Center1 papers (2025–2025) · 1 papers (2020–2020) · 1 papers (2020–2020)Roberta Zanotti · University of Michigan–Ann Arbor1 papers (2020–2020)Daniel J. DeAngelo · Harvard University1 papers (2019–2019)Peter Mollee · The University of Queensland1 papers (2015–2015)Ulrich Dührsen · Klinikum Magdeburg1 papers (2015–2015)Peter Schlattmann · Jena University Hospital1 papers (2015–2015)Gilles Salles · Universidade Federal do Estado do Rio de Janeiro1 papers (2015–2015) · 1 papers (2020–2020)